Brief: FDA Approves Gazyva To Treat Idiopathic Nephrotic Syndrome In Patients 2 Years And Older
25/09/2026 19:41
BRIEF-FDA Approves Gazyva To Treat Idiopathic Nephrotic Syndrome In Patients 2 Years And Older Sept 25 (Reuters) - FDA:
FDA : APPROVES GAZYVA (OBINUTUZUMAB) TO REDUCE RELAPSE RISK IN PEDIATRIC/ADULT IDIOPATHIC NEPHROTIC SYNDROME PATIENTS 2+ YEARS
FDA: GAZYVA CARRIES BOXED WARNING FOR HEPATITIS B REACTIVATION AND PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY
Further company coverage: ROPC.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey